Case Report

Hypertrophic cardiomyopathy in a patient with secondary hypoparathyroidism: A case report✩,✩✩

Juan Felipe Betancur, MDa,*, Christian Adams-Sánchez, MDb, Lina Restrepo-Giraldo, MDC, Joel Arévalo-Novoa, MDb, Beatriz Ramírez, MSc, Juan Felipe Llano, MDf, Gustavo Adolfo López, MDb

a Leader Internal Medicine Research Group, Ayudas Diagnosticas SURA Biociencias I+D, Internal Medicine Department, Clínica Medellín – Grupo Quirónsalud, CES University, Medellín, Colombia
b Cardiology Department, Clínica Cardiofántil, Bogotá, Colombia
c Endocrinology Department, Laboratorio Hematológico, Medellín, Colombia
d Head and Neck Surgery Department, Clínica Medellín – Grupo Quirónsalud, Medellín, Colombia
e Epidemiology Department, Clínica Medellín – Grupo Quirónsalud, CES University, Medellín, Colombia
f Clinical Research Unit, Clínica Medellín – Grupo Quirónsalud, Medellín, Colombia

A B S T R A C T

Parathyroid hormone (PTH) has direct and indirect actions on cardiovascular cells. The effects of chronic hypoparathyroidism on cardiac morphology, function, and conduction are still unclear. Low PTH states are associated with multiple manifestations in the heart, acute or chronic. Acute hypocalcemic cardiomyopathy is a transient dilated cardiomyopathy with reduced ejection fraction and diffuse left ventricular hypokinesia. Chronic hypoparathyroidism-associated cardiomyopathy is a rare disease that may cause reduced myocardial tension, cardiac cavity enlargement, arrhythmias, and congestive heart failure. Here, we describe a 73-year-old woman with chronic hypoparathyroidism and hypocalcemia, who developed a hypertrophic cardiomyopathy, and not a dilated hypocalcemia-associated cardiomyopathy, which would be usually the case.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Hypoparathyroidism is a rare disorder characterized by low or absent concentrations of circulating parathyroid hormone (PTH), leading to hypocalcemia, hyperphosphatemia, and elevated urine fractional excretion of calcium [1]. With an estimated prevalence of 23-37 cases per 100,000 person-years [2], the major cause is iatrogenic, since 78% of the cases occur as a complication of anterior neck surgery [2,3]. Most of car-

✩ Competing Interests: The authors declare that they have no conflict of interest.
✩✩ Funding: None.
* Corresponding author.
E-mail address: juanfebp@hotmail.com (J.F. Betancur).
https://doi.org/10.1016/j.radcr.2022.08.092
1930-0433/© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
diac effects from hypoparathyroidism stem from the resulting hypocalcemia. PTH also appears to have an independent effect on cardiac cells, which has to be elucidated [4].

**Case presentation**

A 73-year-old woman was repeatedly admitted due to recurrent transudate-type pleural effusions, dyspnea, and hypocalcemia. She had a previous history of hypertension, bilateral cataracts, epilepsy, cognitive impairment, and secondary hypoparathyroidism after subtotal thyroidectomy 54 years ago. The patient was under treatment due to chronic heart failure, so she attended our institution because of suspected decompensated heart failure. Physical examination revealed Trousseau and Chvostek signs. Relevant test results showed: corrected calcium 5.42 mg/dL (8.8-10.2), phosphate 7 mg/dL (2.5-4.5), calcium/phosphate product 37.94 (less than 55), TSH 1.65 mU/L (0.350-4.94), and parathyroid hormone <3 pg/mL (15-65).

Chest X-ray (Fig. 1) disclosed cardiomegaly, left pleural effusion, and a band of coarse calcification over the expected location of the mitral valve annulus. Transthoracic echocardiography showed a non-dilated left ventricle with an ejection fraction of 65%, hyperdynamic systolic function with obliteration of the middle ventricular third in the apical portion, and a maximum gradient of 8 mmHg. The mitral valve had severe calcification of the posterior ring. There was tricuspid valve regurgitation with mild right ventricle dilatation. Left and right atrium presented mild and severe dilatation respectively. The pulmonary artery pressure was 75 mmHg. A predominantly apical hypertrophic cardiomyopathy was diagnosed, due to obliteration of the apical cavity of the left ventricle during systole. Gadolinium cardiac MRI (CMRI) (Fig. 2) demonstrated normal biventricular systolic function—with an ejection fraction of 89% and 68% in the left and right ventricle respectively—restrictive pattern with bi-auricular dilatation, and mid-diastolic collapse of the left ventricle with flow acceleration. There was interatrial septal thickness and hypointense nodular thickening of the mitral valve suggestive of calcification. Myocardial perfusion was normal. Non-contrast Brain CT (Fig. 3) showed bilateral symmetric calcifications on basal ganglia compatible with Fahr syndrome. Congo red and crystal violet stains of the periumbilical skin and rectal mucosa were negative, ruling out amyloidosis. Other hypertrophic cardiomyopathy phenocopy conditions like Fabry, glycosogen, and lysosomal storage diseases were also ruled out.

The patient was treated with calcium, calcitriol, and recombinant human PTH (rhPTH) 1-34 fragment (teriparatide, Forteo by Lilly France SAS, Fegersheim, France), at a dose of 20 μg twice daily, as an off-label use due to unavailability of rhPTH 1-84 fragment. These interventions al-
Discussion

Parathyroid hormone has direct and indirect actions on cardiovascular cells (cardiomyocytes and smooth muscle cells) through downstream signaling of heart G protein-coupled receptors. Such actions exert changes in contractility, proliferation, and hypertrophy of the cardiac myocytes [4,5]. On the vasculature, PTH is a vasorelaxant agent acting directly on vascular smooth muscle cells [4,5]. The effects of excess PTH on the cardiovascular system are well-known and are associated with a higher incidence of hypertension, left ventricular hypertrophy, heart failure, arrhythmias, and calcific valve disease [4]. On the other hand, the effects of the chronic deficit of PTH on cardiac morphology, function and conduction is still unclear.

Hypoparathyroidism is an uncommon condition characterized by low or absent PTH levels, hypocalcemia, and hyperphosphatemia; its etiology can be either congenital or acquired [1]. Low PTH states are associated with multiple manifestations on the heart, either acute or chronic. The hypocalcemic cardiomyopathy is an acute, transient, dilated cardiomyopathy with reduced ejection fraction and diffuse left ventricle hypokinesia. It is associated with brain calcifications: Fahr Syndrome (20%), cataracts (20%), and cognitive dysfunction (16.5%). Other acute manifestations include Takotsubo cardiomyopathy and arrhythmias [6]. These manifestations share the same physiopathology and are caused by acute effects of hypocalcemia, hypomagnesemia, vitamin D deficiency, and hypoparathyroidism on cardiomyocytes and calcium channels. They are reversible by restoring serum calcium levels [6].
The cardiac manifestation of chronic hypoparathyroidism, with hypocalcemia, is an associated cardiomyopathy with reduced myocardial tension, cardiac cavity enlargement, arrhythmia, and congestive heart failure [6–8]. Hypoparathyroid cardiomyopathy is probably caused by other factors different from the low PTH state, such as an elevated calcium phosphate product, chronic hyperphosphatemia, and elevated levels of Fibroblast growth factor-23 (FGF-23). Here, we presented a patient with chronic hypoparathyroidism and hypocalcemia who developed a hypertrophic cardiomyopathy, and not a dilated hypocalcemia-associated cardiomyopathy, which usually would be the case.

Goals of treatment in hypoparathyroid patients aim to maintain serum calcium levels slightly below the normal range (8.0–8.5 mg/dl), and to keep the calcium phosphate product below 55 mg²/dl² (a threshold extrapolated from patients with chronic kidney disease that prevents the calcium and phosphate in soft tissues). In hypoparathyroid patients, higher product levels are associated with vascular and mitral valve calcification; but even a calcium phosphate product more than 34.5 mg²/dl² is associated with calcification of the basal ganglia. Another goal aims to maintain fasting serum phosphate within normal range or slightly elevated [9]. In hypoparathyroid patients, hyperphosphatemia might act as a cardiac stressor, increasing FGF-23—a bone-secreting hormone that lowers serum phosphate levels—leading to mitral annular calcification and cardiac hypertrophy [10–14].

Fibroblast growth factor-23 might have general pro-inflammatory features that could contribute to cardiac inflammation associated with pathologic hypertrophy. FGF-23 activates fibroblast growth factor receptor 4 (FGFR4) on cardiac myocytes to stimulate the phospholipase Cγ/calcineurin/Nuclear factor of activated T cell signaling axis in myocytes, thereby promoting cardiac hypertrophy [14,15]. Although the prevalence of hypoparathyroidism is low, in cohorts of patients with this condition, the low occurrence of cardiomyopathy suggests that there must be a subtype of vulnerable patients, with risk factors not yet defined [1,16].

Conclusion

The hypoparathyroidism-associated hypertrophic cardiomyopathy is an exotic manifestation of chronic hypoparathyroidism; it is even rarer than hypocalcemic dilated cardiomyopathy. It seems to be the consequence of hypoparathyroidism, a high calcium phosphate product, and hyperphosphatemia, leading to increased FGF-23 and posterior activation of intracellular pathways, causing cardiac hypertrophy.

Patient consent

Informed written consent was obtained from the patient for publication of the case report and all imaging studies. Consent form on record.

Compliance with ethical standards

This article does not contain any studies involving animals, performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Acknowledgments

Our gratitude to Dr. Luis Vicente Syro for his permanent support and corrections to the manuscript. We also want to thank Dr. Alejandro De la Torre and CES University for the institutional support.

References

[1] Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Reijnmark L, et al. Hypoparathyroidism. Nat Rev Dis Prim 2017;3(17055):1–20.
[2] Gafni RI, Collins MT. Hypoparathyroidism. NEJM 2019;380:1738–47. Available from: www.nejm.org.
[3] Gianferotti L, Marcucci G, Brandi ML. Causes and pathophysiology of hypoparathyroidism. Best Pract Res Clin Endocrinol Metab 2018;32(6):909–25 Available from:. doi:10.1016/j.beem.2018.07.001.
[4] Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart disease. Methodist Debakey Cardiovasc J 2017;13(2):49–54.
[5] Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998;37(1):34–41.
[6] Válek M, Roblová L, Raška I, Schaffelhoferová D, Paleček T. Hypocalcaemic cardiomyopathy: a description of two cases and a literature review. ESC Hear Fail 2020;7(3):1291–301.
[7] Wang Y, He K, Wang O, Lin X, Chen S, Jiang Y, et al. Manifestations of left ventricular dysfunction and arrhythmia in patients with chronic hypoparathyroidism and pseudohypoparathyroidism: a preliminary study. BMC Endocr Disord 2020;20(1):1–9.
[8] Zhang W, Xue F, Su Q, Liu X. Hypocalcemic cardiomyopathy after parathyroidectomy in a patient with uremia: a case report and literature review. J Int Med Res 2020;48(7):1–8.
[9] Zavatta G, Clarke BL. Basal ganglia calcification in hypoparathyroidism and pseudohypoparathyroidism: local and systemic metabolic mechanisms. J Endocrinol Investig 2021;44(2):245–53 Available from:. doi:10.1007/s40618-020-01355-w.
[10] Massera D, Kizer JR, Dweck MR. Mechanisms of mitral annular calcification. Trends Cardiovasc Med 2020;30(5):289–95.
[11] Linefsky JP, OBrien KD, Katz R, De Boer IH, Barash E, Jenny NS, et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification. Am Coll Cardiol 2011;58(3):291–7.
[12] Bollerslev J, Sjöstedt E, Rejnmark L. Cardiovascular consequences of parathyroid disorders in adults. Ann Endocrinol (Paris) 2021;82(3–4):151–7 Available from:. doi:10.1016/j.ando.2020.02.003.

[13] Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, et al. Risk of cardiovascular conditions in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther 2021;38(8):4246–57 Available from:. doi:10.1007/s12325-021-01787-7.

[14] Faul C. Cardiac actions of fibroblast growth factor 23. Bone 2017;100:69–79.

[15] Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015;22(6):1020–32.

[16] Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 2012;97(12):4507–14.